Abstract
To the editor: In the recent report by Singla et al. ([8][1]), the authors seek to determine the effect of transplanted embryonic stem cells (ESCs) on left ventricular remodeling after myocardial infarction in the mouse. They conclude that ESC treatment results in significantly less apoptosis, hypertrophy, and fibrosis. However, an interpretation is complicated by the difference in infarct size: 23 ± 3% in ESC-treated mice compared with 43 ± 8% in controls. The authors claim this difference is an effect of ESC treatment; however, this makes a major assumption, that the original pretreatment infarct size (area at risk) was identical in both groups. If by chance the area at risk was less in the ESC-treated group, then this alone could explain all of the beneficial effects attributed to ESC treatment. So, is this assumption valid? The coronary artery ligation model is well known for producing a wide range of infarct sizes, anywhere between 10–70%, even when the suture is placed in an identical location ([3][2], [7][3]). This is due to differences in coronary branching patterns that are evident even between littermates ([2][4]). Therefore, large-group sizes are necessary for this assumption to be reasonable, but with n = 5 mice in the ESC-treated group and only n = 4 in the control group, this clearly is not the case here. There is also a question mark on the validity of the infarct size measurements that are performed at the end of the study. Sections cut at mid-papillary muscle level are assumed to be representative of the entire ventricle. Recent evidence suggests that at least seven slices from throughout the heart may be required to accurately determine infarct size ([9][5]). Another reason to doubt this approach is that mice commonly develop apical aneurysms ([3][2]) which contribute significantly to infarct size but will not be reflected in an estimate based on mid-papillary muscle sections. Even if both of the above assumptions are correct, i.e., that the initial area at risk was identical and that the observed difference in infarct size is real and due to ESC treatment, there is then the important question of whether the observed reductions in apoptosis, fibrosis, and hypertrophy are simply knock-on effects of a smaller infarct size. Singla et al. ([8][1]) suggest a direct effect of ESC treatment since there was no correlation between infarct size and the number of apoptotic nuclei. This is a disingenuous argument, since there are insufficient numbers in either group for correlation analysis, and if the groups were combined, then there does appear to be a strong correlation. It also runs contrary to the literature where apoptosis has been previously shown to correlate with ventricular remodeling ([1][6], [6][7]), which, in turn, correlates with infarct size ([4][8], [5][9], [7][3]). I believe that in a study such as this, where the entire message is dependent on several key assumptions, it is imperative that more consideration be given to whether these assumptions are indeed valid. 1. [↵][10] Abbate A , Biondi-Zoccai GG, Bussani R, Dobrina A, Camilot D, Feroce F, Rossiello R, Baldi F, Silvestri F, Biasucci LM, Baldi A. Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure. J Am Coll Cardiol 41: 753–760, 2003. [OpenUrl][11][Abstract/FREE Full Text][12] 2. [↵][13] Ahn D , Cheng L, Moon C, Spurgeon H, Lakatta EG, Talan MI. Induction of myocardial infarcts of a predictable size and location by branch pattern probability-assisted coronary ligation in C57BL/6 mice. Am J Physiol Heart Circ Physiol 286: H1201–H1207, 2004. [OpenUrl][14][Abstract/FREE Full Text][15] 3. [↵][16] Dawson D , Lygate CA, Saunders J, Schneider JE, Ye X, Hulbert K, Noble JA, Neubauer S. Quantitative 3-dimensional echocardiography for accurate and rapid cardiac phenotype characterization in mice. Circulation 110: 1632–1637, 2004. [OpenUrl][17][Abstract/FREE Full Text][18] 4. [↵][19] Gao XM , Dart AM, Dewar E, Jennings G, Du XJ. Serial echocardiographic assessment of left ventricular dimensions and function after myocardial infarction in mice. Cardiovasc Res 45: 330–338, 2000. [OpenUrl][20][Abstract/FREE Full Text][21] 5. [↵][22] Kanno S , Lerner DL, Schuessler RB, Betsuyaku T, Yamada KA, Saffitz JE, Kovacs A. Echocardiographic evaluation of ventricular remodeling in a mouse model of myocardial infarction. J Am Soc Echocardiogr 15: 601–609, 2002. [OpenUrl][23][CrossRef][24][Medline][25][Web of Science][26] 6. [↵][27] Palojoki E , Saraste A, Eriksson A, Pulkki K, Kallajoki M, Voipio-Pulkki LM, Tikkanen I. Cardiomyocyte apoptosis and ventricular remodeling after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 280: H2726–H2731, 2001. [OpenUrl][28][Abstract/FREE Full Text][29] 7. [↵][30] Patten RD , Aronovitz MJ, Deras Mejia L, Pandian NG, Hanak GG, Smith JJ, Mendelsohn ME, Konstam MA. Ventricular remodeling in a mouse model of myocardial infarction. Am J Physiol Heart Circ Physiol 274: H1812–H1820, 1998. [OpenUrl][31][Abstract/FREE Full Text][32] 8. [↵][33] Singla DK , Lyons GE, Kamp TJ. Transplanted embryonic stem cells following mouse myocardial infarction inhibit apoptosis and cardiac remodeling. Am J Physiol Heart Circ Physiol 293: H1308–H1314, 2007. [OpenUrl][34][Abstract/FREE Full Text][35] 9. [↵][36] Takagawa J , Zhang Y, Wong ML, Sievers RE, Kapasi NK, Wang Y, Yeghiazarians Y, Lee RJ, Grossman W, Springer ML. Myocardial infarct size measurement in the mouse chronic infarction model: comparison of area- and length-based approaches. J Appl Physiol 102: 2104–2111, 2007. [OpenUrl][37][Abstract/FREE Full Text][38] [1]: #ref-8 [2]: #ref-3 [3]: #ref-7 [4]: #ref-2 [5]: #ref-9 [6]: #ref-1 [7]: #ref-6 [8]: #ref-4 [9]: #ref-5 [10]: #xref-ref-1-1 "View reference 1 in text" [11]:...

This publication has 9 references indexed in Scilit: